title: The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit?
authors.affiliation: Ben Franklin House, Suite 314, 834 Chestnut St, Philadelphia, PA 19107, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Chapman
authors.forename: Lee
authors.initials: L
authors.lastname: Cranmer
authors.forename: W G
authors.initials: WG
authors.lastname: Dixon
authors.forename: K L
authors.initials: KL
authors.lastname: Hyrich
authors.forename: John R
authors.initials: JR
authors.lastname: Patterson
authors.forename: D P M
authors.initials: DP
authors.lastname: Symmons
authors.forename: Mary
authors.initials: M
authors.lastname: Toporcer
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mastrangelo
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000473:pathology; D008545:Melanoma / Q000473:pathology; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors*; D012306:Risk; D012878:Skin Neoplasms / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; D018124:Receptors, Tumor Necrosis Factor